Loading...
XHKG6160
Market cap1.54bUSD
Dec 20, Last price  
104.70HKD
1D
-1.04%
1Q
-15.02%
IPO
-2.15%
Name

Beigene Ltd

Chart & Performance

D1W1MN
XHKG:6160 chart
P/E
P/S
4.54
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
13.49%
Rev. gr., 5y
65.47%
Revenues
2.46b
+73.65%
11,148,00013,035,0008,816,0001,070,000238,387,000198,220,000428,212,000308,874,0001,176,283,0001,415,921,0002,458,779,000
Net income
-882m
L-56.00%
-7,494,000-18,278,000-57,102,000-119,217,000-93,105,000-673,769,000-950,578,000-1,600,523,000-1,413,354,000-2,003,815,000-881,708,000
CFO
-1.16b
L-22.66%
4,073,000-8,694,000-39,843,000-89,513,00012,752,000-547,717,000-750,269,000-1,283,461,000-1,298,723,000-1,496,619,000-1,157,453,000
Earnings
Feb 24, 2025

Profile

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
IPO date
Feb 03, 2016
Employees
10,000
Domiciled in
KY
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,458,779
73.65%
1,415,921
20.37%
1,176,283
280.83%
Cost of revenue
2,158,514
3,567,491
3,083,384
Unusual Expense (Income)
NOPBT
300,265
(2,151,570)
(1,907,101)
NOPBT Margin
12.21%
Operating Taxes
55,872
42,778
(25,234)
Tax Rate
18.61%
NOPAT
244,393
(2,194,348)
(1,881,867)
Net income
(881,708)
-56.00%
(2,003,815)
41.78%
(1,413,354)
-11.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
55,712
46,964
3,442,616
BB yield
-3.85%
-2.69%
-178.03%
Debt
Debt current
732,266
353,010
449,490
Long-term debt
264,070
596,675
310,120
Deferred revenue
300
80,202
266,641
Other long-term liabilities
221,172
343,600
277,443
Net debt
(2,267,708)
(3,682,382)
(5,966,031)
Cash flow
Cash from operating activities
(1,157,453)
(1,496,619)
(1,298,723)
CAPEX
(561,896)
(469,099)
(314,851)
Cash from investing activities
60,004
1,077,123
640,659
Cash from financing activities
416,478
(18,971)
3,636,911
FCF
(348,466)
(2,353,550)
(2,122,313)
Balance
Cash
3,174,400
4,540,288
6,624,849
Long term investments
89,644
91,779
100,792
Excess cash
3,141,105
4,561,271
6,666,827
Stockholders' equity
(8,061,361)
(7,157,624)
(4,948,020)
Invested Capital
12,772,295
12,811,904
12,362,679
ROIC
1.91%
ROCE
6.35%
EV
Common stock shares outstanding
104,387
103,133
92,785
Price
13.87
-18.00%
16.92
-18.82%
20.84
4.85%
Market cap
1,448,253
-17.00%
1,744,852
-9.77%
1,933,719
16.55%
EV
(819,455)
(1,937,530)
(4,032,312)
EBITDA
387,940
(2,085,292)
(1,860,644)
EV/EBITDA
0.93
2.17
Interest
52,480
15,757
Interest/NOPBT